Torii Pharmaceutical Co., Ltd.
Tokyo Stock ExchangeTotal Valuation
Torii Pharmaceutical Co., Ltd. carries a market capitalization of 178.53B, placing it among publicly traded companies globally. Its enterprise value stands at 59.72B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 178.53B |
| Enterprise Value | 59.72B |
Share Statistics
Torii Pharmaceutical Co., Ltd. currently has 14.00 shares outstanding.
| Shares Outstanding | 14.00 |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Torii Pharmaceutical Co., Ltd. trades at a trailing price-to-earnings ratio of 19.39. The price-to-sales ratio is 1.78, and the price-to-book ratio stands at 0.89.
| PE Ratio | 19.39 |
| PS Ratio | 1.78 |
| PB Ratio | 0.89 |
| P/TBV Ratio | 0.85 |
| P/FCF Ratio | N/A |
| P/OCF Ratio | N/A |
Enterprise Valuation
The EV/Sales ratio of 1.04 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 8.95 provides insight into valuation relative to core operating earnings.
| EV / Sales | 1.04 |
| EV / EBITDA | 8.95 |
| EV / EBIT | 8.95 |
| EV / FCF | N/A |
Financial Position
Torii Pharmaceutical Co., Ltd. maintains a current ratio of 6.60, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 6.60 |
| Quick Ratio | 3.19 |
| Debt / Equity | N/A |
| Debt / EBITDA | N/A |
| Interest Coverage | N/A |
Financial Efficiency
Torii Pharmaceutical Co., Ltd. posts a return on equity of 4.61 and a return on invested capital of 4.15.
| Return on Equity (ROE) | 4.61 |
| Return on Assets (ROA) | 3.95 |
| Return on Invested Capital (ROIC) | 4.15 |
| Return on Capital Employed (ROCE) | 4.61 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 2.79 |
Taxes
Over the trailing twelve months, Torii Pharmaceutical Co., Ltd. has paid 1.78B in income taxes, reflecting an effective tax rate of 25.25.
| Income Tax | 1.78B |
| Effective Tax Rate | 25.25 |
Stock Price Statistics
Torii Pharmaceutical Co., Ltd.'s stock has declined approximately -99.99992% over the past 52 weeks. The 50-day moving average sits at 244.47M, while the 200-day moving average is 61.12M.
| Beta (5Y) | N/A |
| 52-Week Price Change | -99.99992% |
| 50-Day Moving Average | 244.47M |
| 200-Day Moving Average | 61.12M |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Torii Pharmaceutical Co., Ltd. generated 57.25B in revenue and converted that into 5.25B in net income, yielding earnings per share of 186.94. EBITDA reached 6.67B, while operating income came in at 6.67B.
| Revenue | 57.25B |
| Gross Profit | 25.47B |
| Operating Income | 6.67B |
| Pretax Income | 7.03B |
| Net Income | 5.25B |
| EBITDA | 6.67B |
| EBIT | 6.67B |
| Earnings Per Share (EPS) | 186.94 |
Balance Sheet
Total book value stands at 114.87B, with working capital of 73.96B providing operational flexibility.
| Cash & Cash Equivalents | 42.17B |
| Total Debt | N/A |
| Net Debt | -3.18B |
| Equity (Book Value) | 114.87B |
| Book Value Per Share | 4,087.12 |
| Working Capital | 73.96B |
Margins
Torii Pharmaceutical Co., Ltd. operates with a gross margin of 44.49, reflecting its pricing power and cost economics. The operating margin of 11.65 and net profit margin of 9.18 provide insight into operational efficiency.
| Gross Margin | 44.49 |
| Operating Margin | 11.65 |
| Pretax Margin | 12.28 |
| Profit Margin | 9.18 |
| EBITDA Margin | 11.65 |
Scores
Torii Pharmaceutical Co., Ltd. posts an Altman Z-Score of 6.80, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 6.80 |